Table 3.

Tolerability of Neoadjuvant Therapy and Transplant Outcomes

Adverse Events (total)	35
SAEs (total)	14
SAE per Patient (range)	1 (0–6)
Other AEs (total)	21
AE per Patient (range)	2 (0–8)
Most Frequent AEs (% of treated patients)
Cholangitis	6 (50)
Plantar/Palmar Erythrodysesthesia	6 (50)
Diarrhea	2 (17)
Wound Infection (post staging procedure)	2 (17)
Dose Reductions	5
Biliary Interventions (mean)	7
Total Transplants	6
Mean Wait Time (days)	92
Cold Ischemia Time (mean min.)	344
Warm Ischemia Time (mean min.)	27
Length of Stay (median)	12.5
Post-transplant Complications	11
One Year Survival (%)	83
Tumor Explant Pathology
Tumor Size (mean cm)	1.95
Neurovascular Invasion (no. patients)	3
Positive Lymph Node (no. patients)	1
Complete Response (%)	1 (17)
Partial Response (%)	4 (67)
No Response (%)	1 (17)